Physician profile
Benjamin Addy
NPI 1831520782
$377,146.91
in general payments reported to CMS, 2019-2025
35 companies · $106K in 2025
The $106K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41K · 2022: $37K · 2023: $74K · 2024: $119K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $224K · Travel and Lodging: $26K · Food and Beverage: $26K · Honoraria: $16K · Consulting Fee: $5,768 · Education: $458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $224,206.00 |
| Travel and Lodging | $26,472.66 |
| Food and Beverage | $26,125.46 |
| Honoraria | $15,950.00 |
| Consulting Fee | $5,767.50 |
| Education | $457.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $98,454.41 | 2021-2025 | Aklief, Nemluvio, Twyneo |
| Ucb, INC. | $83,929.79 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $66,730.48 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Dermavant Sciences, INC. | $51,134.55 | 2022-2024 | Vtama |
| Janssen Scientific Affairs, LLC | $32,919.76 | 2021-2023 | Tremfya |
| Organon LLC | $19,318.47 | 2023-2025 | Vtama, Nexplanon, Hadlima |
| Abbvie INC. | $5,723.51 | 2021-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $2,280.53 | 2021-2025 | Adbry, Anzupgo, Spevigo |
| Novartis Pharmaceuticals Corporation | $2,275.85 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,192.80 | 2021-2025 | Dupixent, Libtayo |
| Incyte Corporation | $2,032.71 | 2021-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $1,795.09 | 2021-2025 | Ilumya |
| Amgen INC. | $1,325.06 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $1,123.31 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $938.13 | 2022-2025 | Sotyktu |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $928.02 | 2021-2025 | |
| Lilly USA, LLC | $872.14 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $750.07 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $750.00 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $391.40 | 2021-2025 | Siliq, Jublia, Cabtreo |
| Epi Health, LLC | $362.59 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $213.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.59 | 2022-2025 | Spevigo |
| Mayne Pharma Commercial LLC | $187.40 | 2021-2023 | |
| Verrica Pharmaceuticals INC. | $84.87 | 2023-2025 | Ycanth |
| Mylan Institutional INC. | $39.62 | 2023 | Hulio |
| Smith+Nephew, INC. | $33.52 | 2022 | |
| Kerecis Limited | $28.73 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Fresenius Kabi USA, LLC | $25.66 | 2024 | Idacio |
| Biocon Biologics INC | $24.42 | 2025 | Yesintek |
| Botanix Sb INC | $16.70 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $16.31 | 2022 | |
| Biofrontera INC. | $16.16 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Scynexis, INC. | $14.39 | 2022 | |
| Access Pro Medical, LLC | $14.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Addy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.